Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome

Abstract

Metabolic syndrome (MetS) and obesity represent a public health problem worldwide. Bioelectrical impedance analysis (BIA) is a practical and effective way of evaluating body composition, especially abdominal fat. Liraglutide, a GLP-1 analog, reduces body weight and improves cardiometabolic parameters. In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46). The groups were statistically similar with regard to the age of females (p = 0.852) and males (p = 0.657). Almost all anthropometric and BIA variables were higher in the treatment group than in the comparative group (p < 0.05). Abdominal circumference (AC) decreased significantly more in the treatment group. In males, body weight and fat mass also decreased (p < 0.05). Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (p < 0.05). AC and FMT were strongly correlated (rho = 0.531, p < 0.001) in the treatment group. In the multiple regression analysis, liraglutide treatment remained independently associated with FMT. Treatment with liraglutide for 6 months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes.

Type 2 Diabetes Mellitus and Cardiometabolic Prospects: A Rapid Narrative Review

“…Health professionals should receive educational intervention to counsel their patients on building healthy eating habits and increasing physical activity to defend themselves from the atrocities of T2DM and CMS [ 98 - 103 ]. Obesity and CMS-related clinical trials published and indexed in PubMed in the last year ( https://pubmed.ncbi.nlm.nih.gov /?term=Obesity%2C%20Cardiometabolic%20Syndrome&filter=simsearch2.ffrft&filter=pubt.clinicaltrial&filter=datese, accessed June 30, 2024) are depicted in Table 1 [ 104 - 138 ].…”